uracil has been researched along with Angiogenesis, Pathologic in 17 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 9.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 5.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4." | 3.91 | Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. ( Cruz-Muñoz, W; Hileeto, D; Kerbel, RS; Man, S; Muñoz, R; Viloria-Petit, A; Wood, GA; Xu, P, 2019) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "On using low TP-expressing tumors and TP blocking studies as controls, minor TP-specific accumulation of the radiotracer was detected in these studies." | 1.36 | In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging. ( Akizawa, H; Kuge, Y; Nishijima, K; Ohkura, K; Seki, K; Takahashi, M; Tamaki, N; Zhao, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, XY | 1 |
| Zhang, TJ | 1 |
| Kamara, MO | 1 |
| Lu, GQ | 1 |
| Xu, HL | 1 |
| Wang, DP | 1 |
| Meng, FH | 1 |
| Muñoz, R | 1 |
| Hileeto, D | 1 |
| Cruz-Muñoz, W | 1 |
| Wood, GA | 1 |
| Xu, P | 2 |
| Man, S | 2 |
| Viloria-Petit, A | 1 |
| Kerbel, RS | 2 |
| Tang, TC | 1 |
| Lee, CR | 1 |
| Akizawa, H | 1 |
| Zhao, S | 1 |
| Takahashi, M | 1 |
| Nishijima, K | 1 |
| Kuge, Y | 1 |
| Tamaki, N | 1 |
| Seki, K | 1 |
| Ohkura, K | 1 |
| Hsu, CY | 1 |
| Shen, YC | 1 |
| Yu, CW | 1 |
| Hsu, C | 1 |
| Hu, FC | 1 |
| Hsu, CH | 1 |
| Chen, BB | 1 |
| Wei, SY | 1 |
| Cheng, AL | 1 |
| Shih, TT | 1 |
| Tanaka, F | 1 |
| Yanagihara, K | 1 |
| Otake, Y | 1 |
| Miyahara, R | 1 |
| Wada, H | 1 |
| Wei, J | 1 |
| Blum, S | 1 |
| Unger, M | 1 |
| Jarmy, G | 1 |
| Lamparter, M | 1 |
| Geishauser, A | 1 |
| Vlastos, GA | 1 |
| Chan, G | 1 |
| Fischer, KD | 1 |
| Rattat, D | 1 |
| Debatin, KM | 1 |
| Hatzopoulos, AK | 1 |
| Beltinger, C | 1 |
| Weiss, GR | 1 |
| Burris, HA | 1 |
| Eckhardt, SG | 1 |
| Rodriguez, GI | 1 |
| Sharma, S | 1 |
| Valley, A | 1 |
| Hirota, K | 1 |
| Sawada, M | 1 |
| Sajiki, H | 1 |
| Sako, M | 1 |
| Matsushita, S | 1 |
| Nitanda, T | 1 |
| Furukawa, T | 1 |
| Sumizawa, T | 1 |
| Tani, A | 1 |
| Nishimoto, K | 1 |
| Akiba, S | 1 |
| Miyadera, K | 5 |
| Fukushima, M | 2 |
| Yamada, Y | 6 |
| Yoshida, H | 1 |
| Kanzaki, T | 1 |
| Akiyama, S | 1 |
| Yonekura, K | 5 |
| Basaki, Y | 5 |
| Chikahisa, L | 4 |
| Okabe, S | 4 |
| Hashimoto, A | 5 |
| Wierzba, K | 3 |
| Shibata, J | 2 |
| Murakami, K | 1 |
| Aoyagi, K | 3 |
| Focher, F | 1 |
| Ubiali, D | 1 |
| Pregnolato, M | 1 |
| Zhi, C | 1 |
| Gambino, J | 1 |
| Wright, GE | 1 |
| Spadari, S | 1 |
| Murray, PE | 1 |
| McNally, VA | 1 |
| Lockyer, SD | 1 |
| Williams, KJ | 1 |
| Stratford, IJ | 1 |
| Jaffar, M | 1 |
| Freeman, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma[NCT00464919] | Phase 2 | 50 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for uracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2004 |
New anticancer agents.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Humans; Lactones; Macrolides; Neovascularization, Patho | 1997 |
1 trial available for uracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2011 |
14 other studies available for uracil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Mo | 2019 |
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2019 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging.
Topics: Animals; Biological Transport; Cell Line, Tumor; Enzyme Inhibitors; Female; Gene Expression Regulati | 2010 |
Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery.
Topics: Animals; Bone Neoplasms; Bystander Effect; Carcinoma, Lewis Lung; Cell Hypoxia; Cytosine Deaminase; | 2004 |
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Cell Division; Drug Design; Enzyme Inhibitors; Female; Humans; Neov | 1997 |
The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Humans; KB Cells; Male; Mice; Mice, Inbred BALB C; Mic | 1999 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
[Anti-metastatic and anti-angiogenic activity of UFT in a lung spontaneous metastasis model in mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Kidney Neoplasms; Lu | 1999 |
[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Neo | 2000 |
Novel nonsubstrate inhibitors of human thymidine phosphorylase, a potential target for tumor-dependent angiogenesis.
Topics: Amino Acid Sequence; Antineoplastic Agents; Blood Platelets; Cloning, Molecular; Enzyme Inhibitors; | 2000 |
UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Topics: Air Sacs; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Carcinoma, Rena | 2000 |
Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Escherichia coli; Inhibitory Concentration 50; Neovascular | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |